The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...

Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its ...

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What ...

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

Basecamp Research just netted $140 million in a series C fundraising round that valued the company at $800 million, according ...

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven ...

Patients in psychedelic trials often know if they’re taking the study drug or a placebo. But trial design changes could ...